A pioneer in thromboembolic disorders
Dr. Hirsh has combined an active laboratory search for new and more effective anti-clotting drugs (low molecular-weight heparins, LMWH) with a wide-ranging clinical study of their effectiveness. As the result of his studies, it has become possible to improve the treatment of deep-vein thrombosis, and to adjust optimally the dosage of oral anti-coagulant medications that reduce the chance of heart and stroke in persons at risk. As Director of the Hamilton Civic Hospital Research Centre at McMaster and as an active partner with several pharmaceutical firms, Dr. Hirsh established the specialty of clinical thrombosis on a firm footing, and fostered a whole generation of young researchers in the field.